Analysts Turn Mixed On Amicus Therapeutics, Inc. (FOLD), NetApp, Inc. (NTAP)
Analysts Turn Mixed On Amicus Therapeutics, Inc. (FOLD), NetApp, Inc. (NTAP). Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 2 believe it has the potential for further growth, thus rating it as Hold while 6 advised investors to purchase the stock. During the trading session, a total of 3.28 million shares were traded which represents a -6.34% decline from the average session volume which is 3.08M shares. Cantor Fitzgerald also rated NTAP as Initiated on January 30th, 2019, with its price target of $14 suggesting that NTAP could surge by 4.1% from its current share price. Even though the stock has been trading at $74.25/share, analysts expect it to surge higher by 1.67% to reach $78.72/share.